Revenue from operations grew by 17.28% year on year (YoY) to Rs 2,241.75 crore during the quarter, primarily driven by robust growth in CDMO business. The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 1,324 crore (up 24% YoY), complex hospital generics (CHG) stood at Rs 643 crore (up 9% YoY) and India consumer healthcare (ICH) came in at Rs 277 crore (up 8% YoY) during the period under review. The drug maker's profit before tax soared 203.64% to Rs 120.12 crore in September 2024 quarter from Rs 39.56 crore posted in same quarter a year ago. EBITDA grew 28% YoY to Rs 403 crore with EBITDA margin of 18%, a YoY improvement of over 150 bps, driven by operating leverage, cost optimization initiatives and superior revenue mix. Nandini Piramal, chairperson of Piramal Pharma, said, 'We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation related work and on-patent commercial revenues. To sustain this growth momentum and to capitalize on rising demand for sterile fill-finish capabilities, we have announced a US$80Mn expansion plan at our Lexington facility which is expected to get complete by end FY27. In our CHG business, we are witnessing steady volume growth in inhalation anesthesia products in the US and Emerging Markets. In our ICH business, we continue to see a robust growth in our power brands and e-commerce sales. During the quarter, we released our Sustainability Report for FY24 under the theme, 'Building Resilience for a Sustainable Tomorrow', highlighting our progress on the sustainability initiatives. Over the long term, we remain committed to achieving our financial goals of $2 billion revenue with 25% EBITDA margin and 1x net debt / EBITDA by FY30.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip hit an all time high of Rs 249.60 in today's intraday session.Powered by Capital Market - Live

The headline equity benchmarks traded with minor gains in morning trade. The Nifty traded above the 24,400 level. PSU Bank shares extended gains for the second consecutive trading session. Trading could be volatile due to weekly F&O series expiry today. At 10:30 IST, the barometer index, the S&P BSE Sensex, added 21.40 points or 0.03% to 80,103.38. The Nifty 50 index rose 3.05 points or 0.01% to 24,438.55. The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.40% and the S&P BSE Small-Cap index added 0.27%. The market breadth was positive. On the BSE, 1,836 shares rose and 1,677 shares fell. A total of 159 shares were unchanged. Result today: ITC (down 0.97%), NTPC (up 0.67%), IndusInd Bank (down 0.26%), Radico khaitan (up 1.75%), United Breweries (down 1.37%), Aarti Drugs (down 0.38%), JSW Energy (down 0.66%), ACC (up 1.13%), Apcotex Industries (up 1.68%), Adani Total Gas (up 1.83%), Adani Wilmar (up 0.34%), Bikaji Foods International (up 0.53%), Castrol India (down 1.37%), Chalet Hotels (up 2.74%), CIE Automotive India (up 0.45%), Colgate-Palmolive (INDIA) (down 1.05%), CSB Bank (up 0.69%), Cyient (up 2.87%), DCB Bank (down 0.85%), Dixon Technologies (India) (up 0.74%), Finolex Industries (down 0.10%), Glenmark Life Sciences (down 1.01%), GMR Airports Infrastructure (up 1.40%), Go Digit General Insurance (down 0.37%), Godrej Consumer Products (down 1.10%), Home First Finance Company (down 0.35%) and Strides Pharma Science (up 1.05%) will declare their result later today. Buzzing Index: The Nifty PSU Bank index gained 1.08% to 6,421. The index rallied 1.53% in two consecutive trading sessions. UCO Bank (up 1.36%), Punjab National Bank (up 0.59%), Central Bank of India (up 0.42%), Canara Bank (up 0.41%), State Bank of India (up 0.38%), Bank of Baroda (up 0.35%), Indian Bank (up 0.29%), Punjab & Sind Bank (up 0.06%) advanced. On the other hand, Indian Overseas Bank (down 0.84%), Union Bank of India (down 0.58%) and Bank of Maharashtra (down 0.54%) edged lower. Stocks in Spotlight: Piramal Pharma surged 10.24% after the company's consolidated net profit surged 360% to Rs 23 crore during the quarter as compared with Rs 5 crore posted in corresponding quarter last year. Revenue increased 17% YoY to Rs 2,242 crore in Q2 FY25. Birlasoft slipped 3.71% after the company's consolidated net profit declined 14.66% to Rs 128 crore during the quarter as compared with Rs 150 crore in Q1 FY25. Revenue increased 3.08% QoQ to Rs 1,368 crore during the quarter. United Spirits shed 0.11%. The company's consolidated net profit fell 1.76% to Rs 335 crore during the quarter as compared with Rs 341 crore in Q2 FY24. Revenue (excluding excise duty) fell 0.77% to Rs 2,843 in Q2 FY25 as compared with Rs 2,865 crore in Q2 FY24. Powered by Capital Market - Live

Net profit of Piramal Pharma rose 350.00% to Rs 22.59 crore in the quarter ended September 2024 as against Rs 5.02 crore during the previous quarter ended September 2023. Sales rose 17.28% to Rs 2241.75 crore in the quarter ended September 2024 as against Rs 1911.38 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2241.751911.38 17 OPM %15.2413.90 - PBDT312.34224.07 39 PBT120.1239.56 204 NP22.595.02 350 Powered by Capital Market - Live

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma has unveiled an $80M investment plan to expand its Lexington, Kentucky facility. The site specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products, playing a vital role in Piramal Pharma Solutions integrated antibody‐drug conjugate development and manufacturing program, ADCelerate'. The investment, financed by bank loans and internal accruals, aims to enhance the site's existing capacity and capabilities to meet the demands of a rapidly growing market. With this expansion, Piramal Pharma will strengthen its position as an efficient and reliable global partner for biologic manufacturing, leveraging deep scientific expertise and extensive experience managing complex technical projects.    The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new laboratory, and state‐of‐the‐art machinery to scale clients' products effectively. Key additions include a new filling line, two commercial‐size lyophilizers, a special capping machine, and an external vial washer. Currently, the Lexington site can manufacture 104 product batches per year (utilization at peak levels). Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches. Powered by Capital Market - Live

Net Loss of Piramal Pharma reported to Rs 88.64 crore in the quarter ended June 2024 as against net loss of Rs 98.58 crore during the previous quarter ended June 2023. Sales rose 11.57% to Rs 1951.14 crore in the quarter ended June 2024 as against Rs 1748.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1951.141748.85 12 OPM %10.487.57 - PBDT139.4766.50 110 PBT-45.08-107.11 58 NP-88.64-98.58 10 Powered by Capital Market - Live

Revenue from operations grew by 11.57% year on year (YoY) to Rs 1,951.14 crore during the quarter, driven by robust high-teen growth in the CDMO business and steady double-digit growth in the ICH business. The company's revenue from contract development and manufacturing organization (CDMO) was at Rs 1,057 crore (up 18% YoY), complex hospital generics (CHG) stood at Rs 631 crore (up 2% YoY) and India consumer healthcare (ICH) came in at Rs 264 crore (up 10% YoY) during the period under review. The drug maker posted a pre-tax loss of Rs 45.08 crore in Q1 FY25 as compared with pre-tax loss of Rs 107.11 crore recorded in same quarter last year. EBITDA grew 31% YoY to Rs 224 crore with EBITDA margin of 11%, a YoY improvement of over 170bps, driven by operating leverage, cost optimization measures and superior revenue mix. Nandini Piramal, chairperson of Piramal Pharma, said, 'We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also seeing good demand for our differentiated offerings with increase in customer enquiries and visits. In our CHG business, our planned expansion for inhalation anesthesia portfolio is on track and is expected to get commercialized in FY26. Our India Consumer Healthcare business is also delivering steady growth driven by power brands and strong traction in e-commerce channel. As a responsible organisation, we are taking good strides in our journey towards building sustainable operations. Our continuous efforts in quality and compliance bore fruits with successful closure of USFDA inspections at two of our facilities at Lexington (USA) and PPDS (Analytical Services, India). Historically our H2 outperforms H1, both in terms of revenue and profitability, and we expect this trend to continue in FY25. We intend to further build on to the good start that we have had to the financial year.' Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products. The scrip declined 0.66% to Rs 165.15 on the BSE.Powered by Capital Market - Live

Piramal Pharma has granted 48,30,836 stock options under Employee Stock Option and Incentive Plan on 26 July 2024. Powered by Capital Market - Live

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live